Current status of antimicrobial resistance in Indian healthcare system: combating antimicrobial resistance with precision medicine · Shinde A, Mohan A, Bulusu VM et al.

Impact of AMR on clinical outcomes

People’s health is directly impacted by antibiotic resistance. It impairs our capacity to create a successful treatment strategy to eradicate infectious diseases and lower rates of morbidity and death. Patients who become resistant to many drugs are more likely to experience higher morbidity or even mortality (Cornejo-Juárez et al., 2015). AMR poses a risk to the treatment of pre-operative and post-operative nosocomial infections, making treatments difficult for already debilitated patients. The burden of patient mortality is as high as 13.1% overall in MDR infections, with MDR A. baumanii infections resulting in 2–3 fold higher mortality (29%) (Barrasa-Villar et al., 2017; Massart et al., 2022; Figueiredo Costa, 2008). However, it to be noted that long course colistin treatment over short course for Carbapenem resistant Acinetobacter baumanii proved to be promising and beneficial for critically ill patients and helped in reduction of 30-day mortality rate (aOR = 0.46, 95% CI: 0.26 – 0.83, p = 0.009) amongst the long course colistin group with negligible differences in nephrotoxicity amongst the two groups (aOR 1.28, 95% CI: 0.74 – 2.22, p = 0.368) (Katip et al., 2023).

For hospitalized patients, increased length of ICU stay is higher in patients with HAIs, averaging at 13 days, and is also associated with a higher risk of mortality (Ramsamy et al., 2017). Similarly, for community-acquired infections, MDR infections were associated with inappropriate antibiotic use and were directly related to higher mortality (adjusted odds ratio (aOR), 6.06, 95% CI, 1.2 – 55.7) (Lohiya et al., 2020). Bacteraemia, being a life-threatening condition, often resulting in half of the patients succumbing to illness, requires exhaustive antimicrobial treatment. Due to ever-increasing AMR, antimicrobial therapy is often ineffective resulting in increased patient mortality (Figueiredo Costa, 2008; Ramsamy et al., 2017). Additionally, it makes the treatment plan more difficult for patients with long-term antibiotic-dependent conditions such as tuberculosis, whose prevalence is already rampant in India (Lohiya et al., 2020).

Rural AMR gaps

Antimicrobial resistance (AMR) has become a widespread public health concern across India; however, significant differences in resistance patterns and underlying drivers are observed between rural and urban settings. These variations are influenced by multiple socio-economic, environmental, and healthcare-related factors. Urban areas, in particular, are often densely populated and experience higher levels of environmental pollution, conditions that facilitate the rapid transmission of infectious diseases and potentially accelerate the emergence and spread of AMR (Balachandra et al., 2021).

In contrast, rural areas may have comparatively lower access to antibiotics due to limited healthcare infrastructure; however, inappropriate antibiotic use remains a significant concern. Limited awareness regarding proper antibiotic usage, coupled with widespread over-the-counter (OTC) availability, contributes to misuse in rural India (Sharma et al., 2023a). The situation is particularly alarming in states such as Bihar—India’s third most populous state—where scarce healthcare resources and inadequate infrastructure exacerbate the problem. Evidence indicates a substantial rise in antimicrobial resistance to β-lactams, carbapenems, and fluoroquinolones in Bihar. Methicillin-resistant Staphylococcus aureus (MRSA) prevalence is notably high at 65%, significantly exceeding the national average of 47.8% (Modgil et al., 2025). Furthermore, community-level comparative studies between urban and rural settings demonstrate a consistently higher prevalence of resistant pathogens in rural regions, with rural AMR trends surpassing corresponding data reported by ICMR.

Economic impact of AMR on healthcare

It is now evident that MDR infections take a significant toll on patient and hospital finances. Studies pointing towards increased length-of-stay (LOS) and increased patient mortality can be extrapolated to higher expenditures on patient health (Nathwani et al., 2014). AMR increases the cost of healthcare due to additional nursing and medical care needed for the patient (Pulingam et al., 2022). Treatment of drug-resistant pathogens inadvertently promotes further utilization of antimicrobials to curb the infection. This never-ending cycle results in the burden of purchasing costly antibiotics (Dadgostar, 2019). The median total cost of managing resistant infections in India is calculated at US$ 199 in comparison to US$ 109 for susceptible infections, the median cost of hospitalization per day is US$ 65 and US$ 35 for resistant and susceptible infections respectively. This resulted in heavy economic burdens as nearly half of the patients borrowed money for treatment expenses (Kadam et al., 2024).

Global significance

Outpatient AMR patterns in India provide valuable insights for healthcare professionals worldwide. India’s high antibiotic use and diverse resistance profiles mirror challenges faced by many low- and middle-income countries, offering a model for strengthening global surveillance and stewardship. Data from India support WHO-led initiatives such as GLASS, enhancing evidence-based AMR monitoring and policy development (World Health, 2014; Okeke et al., 2024). The AMR patterns observed in India can help healthcare professionals globally understand prescription trends, antibiotic guideline, and AMSP practice-related resistance mechanisms. Beyond national policy reforms, these insights can inform global antibiotic use strategies and guide the evolution of international frameworks for rational and precision-based antimicrobial therapy.